---
title: "Monte Rosa Therapeutics Appoints Matthew Bowen as Corporate Controller"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275509337.md"
datetime: "2026-02-10T21:02:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275509337.md)
  - [en](https://longbridge.com/en/news/275509337.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275509337.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275509337.md) | [繁體中文](https://longbridge.com/zh-HK/news/275509337.md)


# Monte Rosa Therapeutics Appoints Matthew Bowen as Corporate Controller

Monte Rosa Therapeutics Inc. announced that Edmund Dunn will retire from his role as Senior Vice President, Corporate Controller and Principal Accounting Officer, effective April 3, 2026. Matthew Bowen, who has held various finance roles at the company since 2021, will succeed Dunn in these positions. Bowen previously worked at Ernst & Young LLP and is a licensed Certified Public Accountant. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-044616), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Monte Rosa Therapeutics, Inc. (GLUE.US)](https://longbridge.com/en/quote/GLUE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md)
- [Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC](https://longbridge.com/en/news/281174396.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/en/news/281517197.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)
- [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/en/news/281522861.md)